BACKGROUND-Vagal hyperactivity promotes atrial fibrillation (AF), which has been almost exclusively attributed to acetylcholine. Vasoactive intestinal polypeptide (VIP) and acetylcholine are neurotransmitters co-released during vagal stimulation. Exogenous VIP has been shown to promote AF by shortening action potential duration (APD), increasing APD spatial heterogeneity, and causing intra-atrial conduction block.
Introduction
The intrinsic cardiac neural network is an integral part of the cardiac autonomic network and includes neurons that release noncholinergic and nonadrenergic neural transmitters such as polypeptide Y and vasoactive intestinal polypeptide (VIP). [1] [2] [3] [4] [5] VIP is a 28-base polypeptide that is co-released with acetylcholine (ACh) during vagal stimulation. 6, 7 We recently reported that exogenous VIP affects multiple ionic channels and causes shortening of atrial effective refractory periods (AERPs) and action potential duration (APD), with 1353 increased spatial heterogeneity, and slowing of intra-atrial conduction that precipitates conduction block. 8 Furthermore, VIP perfusion increases the inducibility of atrial fibrillation (AF) by programmed stimulation. 8 VIP also prolongs AF duration. 9 However, data are lacking regarding the effects of neuronally released VIP on the atria during vagal hyperactivity. Our current study aimed to test the hypothesis that, consistent with previously described ionic mechanisms of exogenous VIP effects, 8 neuronally released endogenous VIP may alter the atrial electrophysiologic properties and thereby contributes to the increased vulnerability to AF during vagal stimulation.
Methods

Animal preparation
The experimental protocol was approved by the Institutional Animal Care and Use Committee of Texas Heart Institute in accordance with the Guidelines for the Care and Use of Laboratory Animals (National Research Council). Mongrel dogs (weight 30-35 kg) were randomly assigned among the in vivo and ex vivo groups (see Expanded Methods in Online Supplementary Material).
Vagal stimulation was performed either through decentralized bilateral cervical vagosympathetic trunks (VCNS) or through ganglionated plexuses (GPs) in the pericardial fat-pad (VGPS). The strength of VCNS, 2-ms pulse width at 20 Hz, was set to achieve a 20% drop in heart rate or second-degree atrioventricular block. The strength of VGPS, 2-ms pulse width at 20 Hz, was set to achieve at least a 20-ms increase in PR interval. To assess the contributions of VIP and ACh effects during vagal stimulation, we used a specific competitive antagonist (H9935) of VIP receptors 10 and atropine to block the receptor bindings of the respective transmitters.
Electrophysiologic experiments
During in vivo experiments, AERP was defined as the longest coupling interval (S1-S2) of the extrastimulus that failed to result in atrial capture, with the pacing output set at twice diastolic threshold. Atrial vulnerability window was defined as the range of the coupling intervals, during programmed stimulation from the proximal left inferior pulmonary vein, which resulted in AF lasting > 2 seconds. 11 During ex vivo experiments with optical mapping in isolated atrial preparations with intact coronary supply, 8 APD was quantified as APD 75 , which was defined as the interval between the time of local activation and the time when the optical signal had recovered by 75% from the peak value of upstroke. Local conduction velocity (CV) was calculated as previously described. 12 AF dominant frequencies (DFs) were derived by fast Fourier transform (FFT) on 2-second recordings of optical during AF. 13 The experimental protocol and methods are detailed in the Expanded Methods in the Online Supplementary Material.
Statistical analysis
All data are reported as mean ± SEM. Repeated measure analysis of variance was used for comparisons among multiple groups. A general linear mixed effect model was used to evaluate the effects of VIP antagonist and atropine. All statistical analyses were performed using SAS (version 9.3 for Windows, SAS Institute, Cary, NC). P ≤.05 was considered significant.
Results
Neuronally released VIP contributes to vagal effects on atrial electrophysiologic properties
In vivo experiment-The effects of vagal stimulation of the AERP were quantified by measuring the difference between the AERP values determined immediately before and during VCNS (ΔAERP). ΔAERP was measured at 3 drive cycle lengths of 250, 300, and 350 ms at 3 sites: distal coronary sinus, right atrial appendage, and proximal left inferior pulmonary vein (n = 6; Figure 1 ). ΔAERP was determined during 3 episodes: (1) with infusion of normal saline (VCNS only), (2) with VIP antagonist (VCNS and H9935), and (3) with muscarinic blockade atropine (VCNS and atropine). H9935 significantly attenuated vagally induced ΔAERP at all 3 sites and 3 drive cycle lengths (P < .01), whereas atropine completely abolished ΔAERP (P < .001). Without VCNS, H9935 had no effect on AERP (see Online Supplementary Results, Table 1 ).
Ex vivo experiment-VGPS effect was quantified by ΔAPD 75 , that is the difference between APD 75 determined with and without VGPS at a drive cycle length of 300 ms (n = 8; Figures 2A-2C ). H9935 reduced ΔAPD 75 during VGPS by about 30%, from 31.49 ± 4.6 ms to 21.24 ± 3.8 ms (P <.05 vs VGPS only), whereas atropine completely eliminated VGPS-induced ΔAPD 75 (1.34 ± 1.91 ms, P <.001 vs VGPS only, P < .05 vs VPGS with VIP antagonist; Figure 2D ). H9935 eliminated VGPS-induced reduction of CV (ΔCV: 2.04 ± 5.01 cm/s vs 18.04 ± 2.33 cm/s with VPGS only, P <.001) as well as atropine did (1.31 ± 1.89 cm/s, P < .001 vs VPGS only; Figure 2E ). In addition, VGPS increased both standard deviations of APD (APD-SD) and CV (CV-SD), as indexes of spatial heterogeneity, which was significantly attenuated by H9935 and essentially eliminated by atropine (see Online Supplementary Results, Figure 1 ).
Both ΔAPD and ΔCV recovered toward their baseline values after 15-minute washout (ΔAPD: 36.51 ± 4.38 ms, P = .95; ΔCV: 17.83 ± 4.01 cm/s, P = .95 compared with initial recording during initial VGPS without VIP antagonist or atropine). Without VGPS, H9935 had no effect on APD or CV (see Online Supplementary Results, Tables 2 and 3 ).
Muscarinic modulation of neuronal VIP release during vagal stimulation
In vivo experiment-VCNS significantly increased VIP tissue content in both the left atrium (LA) by 2.60 ± 0.57 ng/g (P < .01) and the right atrium (RA) by 2.07 ± 0.60 ng/g (P < .01; Figures 3A and 3B ). However, with atropine, VCNS failed to significantly increase VIP tissue content (only by 0.67 ± 0.27 ng/g in LA, P = .20; and by 0.83 ± 0.48 ng/g in RA, P = .12). Atropine had no effect on baseline VIP tissue content without VCNS.
Blood samples from 3 sites (aorta root, coronary sinus, and superior vena cava) were collected before and during VCNS, with and without atropine perfusion ( Figure 3C ). Without atropine, VCNS increased plasma VIP concentration by 0.77 ± 0.45 ng/L at the aorta root (P < .01) and by 0.70 ± 0.41 ng/L at the coronary sinus (P < .01) but did not affect the concentration of VIP in the superior vena cava (0.24 ± 0.02 ng/L vs 0.23 ± 0.02 ng/L, P = .45). Atropine did not affect plasma VIP concentration at any of the 3 sites without VCNS but reduced VCNS-induced increase in plasma VIP concentration at the aorta root to 0.43 ± 0.15 ng/L (P < .01 vs VCNS only) and at the coronary sinus to 0.31 ± 0.16 ng/L (P < .01 vs VCNS only).
Ex vivo experiment-Similarly, tissue VIP contents in LA and RA and VIP concentrations in coronary sinus were compared with and without VGPS in Langendorffperfused atria ( Figure 4A ). VGPS increased VIP tissue content by 3.62 ± 01.40 ng/g (P <. 01) in LA and by 3.67 ± 0.84 ng/g (P < .01) in RA, which was almost eliminated by atropine (0.33 ± 1.40 ng/g, P = .45, in LA and 0.62 ± 0.41 ng/g, P = .32 in RA, respectively; Figure  4B ).
In addition, atropine inhibited VGPS-induced increase of VIP concentration in outflow of coronary sinus from 4.49 ± 2.0 ng/ (L•100 g) to 1.35 ± 5.85 ng/(L•100 g) ( Figure 4C ).
After atropine washout, the VGPS-induced increases in VIP tissue contents and concentration in coronary sinus were recovered ( Figures 4B and 4C ). Atropine had no effect on VIP tissue content or concentration in coronary sinus outflow without VGPS.
Neuronally released VIP contributes to vagal effects in atrial fibrillation
In vivo experiment-VCNS increased the atrial vulnerability window (AVW) from 3.3 ± 1.7 ms to 38.0 ± 5.5 ms (ΔAVW: 34.2 ± 6.8 ms, P < .001, n = 6). H9935 significantly attenuated such vagally induced increase in AVW (ΔAVW decreased to 16.7 ± 5.1 ms, P < . 05). In contrast, atropine completely eliminated such increase in AVW (ΔAVW: −1.7 ± 2.1 ms, P < .001). Without VCNS, H9935 had no effects on AVW (ΔAVW: 0.0 ± 2.2 ms, P = . 92).
Ex vivo experiment-Sustained AF was induced with rapid pacing from the proximal left inferior pulmonary vein in 6 dogs during VGPS. No sustained AF was induced without VGPS. Continued VGPS was required for AF maintenance during which the highest values of DFmax were seen in the LA-PV region (17.2 ± 0.94 Hz; Figure 5A ). DFmax was lower in the left atrial appendage (LAA; 13.9 ± 0.89 Hz) and the lowest in the RA (11.8 ± 0.57 Hz; Figure 5B ). H9935 decreased DFmax to 12. 
Discussion
Our major findings are as follows. In the presence of endogenous ACh, neuronally released VIP (1) significantly contributes to vagally induced AERP and atrial APD shortening and conduction slowing and (2) may influence AF maintenance by affecting the DFs during AF. These findings confirm our previous report of exogenous VIP effects on ionic currents and support the physiologic relevance of VIP effects on ionic currents. 8 Furthermore, we demonstrated that muscarinic blockade inhibits neuronal VIP release in the atria and conceals the VIP effects.
Effects of neuronally released endogenous VIP in the atria
Vagal stimulation results in shortened atrial APD and refractoriness with increased spatial heterogeneity and thereby increases vulnerability to AF, which has been mostly attributed to ACh. 3, [14] [15] [16] [17] Our study provides the first evidence that endogenous VIP synergistically contributes to vagally induced AERP/APD shortening (Figure 1 and 3) , which can be accounted for by VIP effect on the slowly activating delayed rectifier potassium current I Ks in the presence of ACh (see Online Supplementary Results, Figure 2 ). VIP increases the spatial heterogeneity of APD distribution, partly due to the uneven expression of VIP receptors among atrial myocytes 8, 18 and the difference in the expression of repolarizing currents, especially I to and I Ks , among different regions of the atria. 8, 19 Rosenshtraukh et al 20, 21 first described vagally induced conduction delay/block. AChinduced increase in sink-to-source mismatch was proposed to account for the vagally induced conduction block during AF. 22 Hirose et al 15 demonstrated that intra-atrial conduction delay/block was more evident during vagal stimulation, when both ACh and VIP are released, than during ACh infusion alone. This difference could be explained by the noncholinergic vagal effects mediated through VIP, which suppresses the sodium current I Na . 8 VIP antagonist could completely abolish the vagal effects on conduction velocity during pacing (Figure 3) , supporting the hypothesis that vagally released VIP contributes significantly to the vagal effect on conduction.
Muscarinic receptor-mediated release of VIP in atria during vagal stimulation
Atropine abolishes all cardiac vagal effects with few exceptions, such as VIP effects on accelerating the sinus rhythm. 7 However, our data during VCNS and VGPS support that VIP contributes to the vagal effects in atria. We further demonstrated that atropine inhibits neuronal VIP release in atrial tissues during vagal stimulation (Figures 3 and 4 ). This represents a novel mechanism by which intra-cardiac neuronal VIP release is mediated and helps to explain how atropine could conceal the effects of VIP in the atria during vagal stimulation. 23, 24 Our data also indicate that a portion of neuronal VIP release may not be mediated by muscarinic receptors as suggested by a trend toward an increased VIP concentration sampled from (1) the aortic root during VCNS, which could be extracardiac as VIP is released from the pulmonary circulation, 25 and (2) the coronary sinus during both VCNS and VGPS with muscarinic blockade. Previous reports have shown that release of VIP into the sinoatrial and atrioventricular nodes is not affected by atropine and that VIP innervations in the sinoatrial and atrioventricular nodes are different from those in the atria. 2, 26, 27 Our hypothesis is further corroborated by previous reports that atropine inhibited vagally induced VIP release from the gastrointestinal track in pigs 28 and in dogs. 29 Furthermore, our data also suggest that VIP-releasing neurons in atria may be governed by a second-order system and, therefore, may be an important component of the local circuit neuron network. 30 This is particularly interesting and potentially significant because VIP release is also increased during acute ischemia and heart failure where local circuit neuron network signaling may be activated and even dysfunctional but parasympathetic tone usually is not increased. may be explained by VIP effects that (1) enhance I Ks and abbreviate APD/ AERP and (2) suppress I Na and slow intra-atrial conduction. 8 Theoretically, slow conduction could result in reduced speed of revolution of rotor(s) and thereby decrease DFs. However, it was shown that DFs are primarily determined by refractoriness of atrial myocardium that limits the maximum frequency of resolution of rotors 31 .
Study limitations
Uncovering the effects of endogenous neural transmitters in vivo or ex vivo depends on the availability of specific receptor antagonist. In addition to evidence reported in the literature, 10, 32 use of H9935 as a specific VIP antagonist was supported by the following: (1) it had no direct effects on the atria without vagal stimulation, (2) the results of our current study with H9935 are consistent with the effects of exogenous VIP in both human and canine atria, 8 and (3) H9935 completely reversed the effects of exogenous VIP (see Online Supplementary Material, Table 3 ).
Pituitary adenylate cyclase-activating polypeptide (PACAP) is the only known non-VIP neural transmitter that may bind with VIP receptors. 33 Previous experiments indicate that PACAP shortens AERP and induces AF by activating postganglionic parasympathetic nerves and, thereby, enhancing ACh release rather than by its direct effect on atrial tissue. 34 PACAP does not affect intra-atrial conduction velocity. 34 We stimulated vagal hyperactivity by neural stimulation but did not examine the effects of ACh perfusion on VIP release. It is possible that an overwhelming amount of exogenous ACh effects could completely overshadow endogenous VIP effects. Furthermore, neuronal VIP release is modulated by the frequency of vagal impulses and might be affected only minimally by ACh perfusion as tonic stimulation. 7 Further studies may be warranted to identify the subtype(s) of muscarinic receptors responsible for modulating neuronal VIP release.
Only the superior and inferior left GPs were simultaneously stimulated in our current study, although there are differences in cardiac response to stimulation of different GPs. 35 It will be important to investigate the role of individual GPs in modulating VIP release in the atria in future studies.
Conclusion
Our study provides the first evidence that neuronally released VIP contributes to vagally induced changes in atrial electro-physiologic properties in the presence of concomitantly released ACh. We further demonstrated that neuronally released VIP may participate in the pathophysiology of vagally induced AF, as suggested by previous studies. 5, 8, 9 Neuronal VIP release in the atria during vagal stimulation is mediated by muscarinic receptors, a novel mechanism by which the effects of neuronally released VIP in the atria are concealed by atropine administration. 
ABBREVIATIONS
CLINICAL PERSPECTIVES
Autonomic dysfunctions, including abnormally increased vagal tone, have been shown to promote atrial fibrillation (AF). Vagal effects in AF have been attributed to the effects of acetylcholine. Our study demonstrated that vagally released noncholinergic neural polypeptide (vasoactive intestinal polypeptide [VIP] also contribute to vagal effects in the atria and provided the first evidence that VIP release in the atria is mediated by muscarinic receptors, a novel mechanism that atropine could conceal VIP effects. A full understanding of all the factors, such as those described in our study, that contribute to the pathogenesis of AF is necessary to provide a mechanistic foundation for advancement of AF management and development of new therapeutic innovations. Further studies of the interaction among various components of the cardiac innervations and the molecular basis of VIP effects including signal transduction pathways will be required to identify potential pharmacologic interventions and to facilitate the translation of research results into clinical practice. 
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